drugset / Trial / NCT05351697
Clinical Study of BR105 Injection
NaSequentialOpen-labelOther
Summary
A phase 1, dose escalation and dose expansion study of BR105 in patients with advanced malignancies.
Timeline
- Start
- 2022-04-19
- Primary completion
- 2025-10-30
- Completion
- 2025-10-30
Outcome
Outcome not reported
Stopped (Business): “Company R\&D Strategy Adjustment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LUMISTOBART | Monoclonal antibody | 0.2 mg/kg | Intravenous |
| Subject | LUMISTOBART | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | LUMISTOBART | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | LUMISTOBART | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | LUMISTOBART | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | LUMISTOBART | Monoclonal antibody | 30 mg/kg | Intravenous |
| Subject | LUMISTOBART | Monoclonal antibody | 40 mg/kg | Intravenous |